Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
How mRNA-LNP Chemistry Shapes Translation
2026-11-19
The translation of mRNA therapeutics depends on more than RNA sequence or particle formation. Lipid ionization, intracellular trafficking, manufacturing history, and orthogonal quality measurements jointly determine whether a formulation can connect molecular design with reproducible biological performance.
mRNA-LNP Translation: What CMC Evidence Shows
2026-11-18
A review-based synthesis of how lipid chemistry, critical quality attributes, manufacturing comparability, and analytical controls shape the translation of mRNA lipid nanoparticles. The evidence concerns mRNA-LNP systems and does not establish performance for cell-freezing media.
What CMC Evidence Really Shows for mRNA-LNPs
2026-11-18
A source-grounded editorial explains how lipid chemistry, manufacturing control, analytical characterization, and physiological stability jointly shape the translation of mRNA lipid nanoparticles—and where current evidence remains qualitative.
How mRNA-LNP Translation Depends on CMC
2026-11-17
A literature-focused analysis of how lipid chemistry, particle attributes, manufacturing comparability, and analytical controls shape the translation of mRNA lipid nanoparticles from research concepts toward clinically credible products.
When Context Changes What an mRNA Result Means
2026-11-17
A result in mRNA delivery is meaningful only when its model, readout, manufacturing context, and intended use are considered together. The evidence distinguishes formulation performance from physiological stability, reproducibility, tolerability, and clinical translation.
What Makes mRNA–LNP Translation Credible?
2026-11-16
A 2026 review frames mRNA–lipid nanoparticle translation as a chain linking lipid chemistry, manufacturing attributes, analytical controls, and clinical performance. Its strongest contribution is a CMC-oriented interpretation of how these factors interact; it does not provide a quantitative head-to-head efficacy analysis for any particular formulation.
What mRNA-LNP Comparisons Really Establish
2026-11-16
Published comparisons support lipid nanoparticles as the most clinically established nonviral delivery platform for mRNA, but they do not resolve how lipid chemistry, manufacturing route, quality attributes, and physiological stability jointly determine clinical performance.
What mRNA-LNP Comparisons Really Establish
2026-11-15
Published comparisons support a trade-off-based view of mRNA delivery: ionizable lipids offer a different balance of delivery, tolerability and clearance than permanently cationic lipids, while lipid nanoparticles retain stronger clinical and regulatory precedent than polymeric or hybrid alternatives. The central uncertainty is not whether one platform is universally best, but how chemistry, critical quality attributes, manufacturing changes and biological context jointly determine performance.
What Controls mRNA–LNP Translation?
2026-11-14
A claim-oriented synthesis of how lipid chemistry, critical quality attributes, manufacturing comparability, and physiological stability shape the translation of mRNA lipid nanoparticles—and where the current evidence remains indirect.
What Controls mRNA–LNP Translation?
2026-11-13
A literature-focused analysis of how lipid chemistry, manufacturing control, analytical characterization, and comparability planning shape the translation of mRNA lipid nanoparticles from delivery concepts into clinically credible products.
Why Context Changes a Scientific Result
2026-11-13
A measurement in RNA delivery acquires meaning from its model, comparator, assay endpoint, manufacturing history, and physiological setting. This editorial examines how those contexts alter interpretation, using a review of mRNA lipid nanoparticle translation as the evidentiary frame.
Multiplex CRISPR: What Comparisons Establish
2026-11-12
Published comparisons support multiplex CRISPR as a flexible platform for coordinated gene disruption, structural-variant modeling and regulatory perturbation. They do not yet establish a universal advantage across cell types, targets or delivery systems. The central unresolved issues are how editing breadth changes specificity and cellular stress, whether reported efficiencies generalize, and how engineering trade-offs affect clinical applicability.
What mRNA-LNP Comparisons Actually Show
2026-11-12
Published comparisons support lipid nanoparticles as the most clinically established mRNA delivery platform, but they do not establish a universal winning lipid, carrier class, or manufacturing route. The central unresolved issue is how molecular design, particle attributes, biological stability, and process history jointly determine clinical performance.
How LNP Chemistry Shapes mRNA Translation
2026-11-11
A mechanistic editorial on how lipid chemistry, particle attributes, physiological stability, and manufacturing controls jointly influence mRNA delivery and clinical translation, while separating established observations from unresolved causal questions.
What mRNA-LNP CMC Evidence Shows
2026-11-11
A source-grounded interpretation of how lipid chemistry, critical quality attributes, manufacturing comparability and stability readouts shape mRNA-LNP translation—and why those findings should not be extended to unrelated cell-freezing materials without direct evidence.